Cetrorelix Acetate (cetrorelix acetate)
LHrH(GNrH) Antagonist, Pituitary Suppressant Agents Subcutaneous Kit
Last reviewed · Source: First Databank (FDB) drug data
Overview
Cetrorelix acetate, a synthetic decapeptide analog of gonadotropin-releasing hormone (GnRH), is a GnRH antagonist.
Cetrorelix acetate, a synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH, luteinizing hormone-releasing hormone, gonadorelin), is a GnRH antagonist.
Cetrorelix competitively blocks GnRH receptors on the anterior pituitary gonadotroph and the subsequent transduction pathway, inducing a rapid, reversible suppression of gonadotropin (luteinizing hormone (LH), follicle-stimulating hormone (FSH)) secretion. The suppression of pituitary LH secretion by cetrorelix is more pronounced than that of FSH. By suppressing the midcycle GnRH-induced surge in LH, cetrorelix can suppress ovulation, oocytic meiosis, and luteinization.
In women undergoing controlled ovarian stimulation, the drug can prevent the LH surges associated with such stimulation and improve implantation and pregnancy rates associated with in vitro fertilization or intracytoplasmic sperm injection (ICSI).
Following subcutaneous administration of a single 3- or 0.25-mg dose of cetrorelix, the onset of action usually occurs within 1 or 2 hours, respectively, and persists for at least 4 days or 24 hours, respectively. Cetrorelix competitively blocks GnRH receptors on the anterior pituitary gonadotroph and the subsequent transduction pathway, inducing a rapid, reversible suppression of gonadotropin (luteinizing hormone (LH), follicle-stimulating hormone (FSH)) secretion. The suppression of pituitary LH secretion by cetrorelix is more pronounced than that of FSH.
By suppressing the midcycle GnRH-induced surge in LH, cetrorelix can suppress ovulation, oocytic meiosis, and luteinization. In women undergoing controlled ovarian stimulation, the drug can prevent the LH surges associated with such stimulation and improve implantation and pregnancy rates associated with in vitro fertilization or intracytoplasmic sperm injection (ICSI).
USES: This medication is used by women having certain fertility treatments (controlled ovarian stimulation). Cetrorelix is usually used in combination with other hormones (FSH and hCG). It works by blocking the release of a certain hormone (luteinizing hormone).
Cetrorelix stops eggs from being released too early and gives the eggs time to grow properly.
Generic name: cetrorelix acetate
Pronunciation: (SE-troe-REL-ix)
Drug class: LHrH(GNrH) Antagonist, Pituitary Suppressant Agents
Therapeutic class: Endocrine
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Cetrorelix Acetate
Indications
The following indications are listed for Cetrorelix Acetate:
- Prevention Of Luteinizing Hormone Surge When Undergoing Controlled Ovarian Hyperstimulation
Also known as: Prevention Of Lh Surge In Coh, Prophylaxis Of Luteinizing Hormone Surge When Undergoing Controlled Ovarian Hyperstimulation.
Dosing
Dosage of cetrorelix acetate is expressed in terms of cetrorelix.
No dosing information is available for this tab.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Cetrorelix Acetate 0.25 Mg Vl | Maintenance | Inject 0.25 mg by subcutaneous route once daily. |
| Drug label | Dosing type | Instructions |
|---|---|---|
| Cetrorelix Acetate 0.25 Mg Vl | Maintenance | Inject 0.25 mg by subcutaneous route once daily. |
Drug interactions
No formal drug interaction studies have been performed.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to cetrorelix acetate, mannitol, or any ingredient in the formulation. Known hypersensitivity to extrinsic peptide hormones, GnRH, or any other GnRH analog. Known or suspected pregnancy or lactation.
- Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min
- Chronic kidney disease stage 5 (failure) GFr<15 ml/min
- Lactation
- Pregnancy
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
Adverse effects occurring in 1% or more of patients receiving cetrorelix include ovarian hyperstimulation syndrome, nausea, and headache.
Less Frequent
- Ovarian hyperstimulation syndrome
Rare or Very Rare
- Anaphylaxis
- Hypersensitivity drug reaction
Rare or Very Rare
- Headache disorder
- Injection site sequelae
- Nausea
Precautions
No enhanced messaging available.
Not indicated.
Category X. (See Users Guide.) May result in fetal loss secondary to antigonadotropic properties. (See Cautions: Contraindications and also Warnings: Fetal/Neonatal Morbidity and Mortality.)
It is not known whether cetrorelix is distributed in milk; use in nursing women is not recommended.
Not indicated for use in geriatric adults 65 years of age and older.
ICD codes
| Code | Type | Description |
|---|---|---|
| Prevention of luteinizing hormone surge when undergoing controlled ovarian hyperstimulation | ||
| Z31.83 | ICD10CM | Encounter for assisted reproductive fertility procedure cycle |
| Z31.89 | ICD10CM | Encounter for other procreative management |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.